Review and Verification Process for Change Management of NMPA Registered Medical Devices in China
分类:公司新闻 发布时间:2024-12-23 16:41:09
In China, the NMPA has a comprehensive system for managing changes to registered medical devices. The process ensures that any change, whether minor or major, does not compromise the device's safety, efficacy, or compliance with Chinese regulations. Manufacturers need to carefully evaluate the nature of the changes and follow the appropriate procedures for notification or application to maintain regulatory compliance and avoid disruptions in market access.

The change management process for NMPA-registered medical devices in China is a critical step to ensure that any modifications made to the product or its manufacturing process do not compromise its safety, efficacy, or compliance with regulatory standards. When a change occurs to a medical device already registered with the National Medical Products Administration (NMPA), it must undergo a review and verification process to determine whether the change is substantial enough to require a new registration, an updated filing, or just a notification.

1. Categories of Changes

Changes to a registered medical device can be categorized as follows:

A. Major Changes (Substantial Changes)

These changes generally require re-registration or a new approval from NMPA. Examples of major changes include:

  • Change in device design or function: This includes significant modifications that alter the intended use, principle of operation, or functionality of the device.
  • Material changes: Substituting a core material or component, especially if it impacts the device’s safety or efficacy.
  • Manufacturing process changes: Any alteration that could impact the product quality, safety, or consistency.
  • Changes in clinical data: Significant updates to clinical trial results or evidence of safety and efficacy.
  • Changes in indications: Expansion or modification of the medical indications or target population.

In these cases, a new application with updated technical documentation and possibly new clinical trials will be required for approval.

B. Minor Changes (Non-Substantial Changes)

These changes typically do not require re-registration but should be reported to NMPA. They may involve:

  • Minor adjustments to labeling: Changes in labeling that do not affect safety or efficacy claims.
  • Changes in non-critical components: Changes to non-critical components or manufacturing equipment that do not affect the quality or performance of the device.
  • Packaging changes: Non-substantial modifications to packaging materials or designs.

These changes may simply require an update to the existing registration, and the manufacturer needs to notify NMPA or submit a modification application.

C. Administrative Changes

Administrative changes involve updates to business registration details, such as:

  • Changes in company address.
  • Changes in company name or legal representative.

These do not usually require a technical review and are mainly for record-keeping purposes.

2. Change Notification or Application Process

Once a change has been identified, the manufacturer or their authorized agent must follow one of these pathways based on the nature of the change:

A. Notification for Minor Changes

  • Minor changes may only require a notification to NMPA, typically done within a specified period (e.g., 30 or 60 days) after the change is made.
  • The notification includes:
    • A description of the change.
    • Documentation showing that the change does not affect the safety, effectiveness, or regulatory compliance of the device.
  • NMPA may then decide whether to accept the change or request additional information.

B. Application for Major Changes

  • For major changes, a detailed application must be submitted to NMPA, which includes:
    • Updated technical documentation (e.g., design, manufacturing process, performance testing, risk analysis).
    • New clinical data (if applicable).
    • Updated labeling and packaging.
    • A change evaluation report that outlines the rationale for the change and its impact on the device's performance and safety.
  • NMPA will then review the application in detail and may ask for further clarifications or additional testing data.
  • If NMPA is satisfied, they will issue an updated registration certificate.

3. Technical Review and Evaluation

NMPA conducts a technical review of the submitted documentation to evaluate the impact of the change on the device's performance, safety, and efficacy. The process includes:

  • Risk assessment: NMPA will assess whether the change introduces new risks or alters the risk profile of the device.
  • Clinical data review: For major changes, updated clinical data or new studies may need to be reviewed to ensure the device continues to meet NMPA standards for safety and performance.
  • Performance testing: If the change affects the device's technical characteristics or intended use, performance testing may be required.
  • Inspection of manufacturing site: If the change involves a modification in manufacturing processes or facilities, NMPA may conduct an inspection of the manufacturing site.

The review process can vary in time, depending on the complexity and scope of the change. For substantial changes, it may take several months for NMPA to finalize their decision.

4. Approval or Rejection

  • If NMPA is satisfied that the change is compliant with the regulatory requirements, they will approve the modification and issue a new registration certificate or update the existing one.
  • In the case of a rejection, NMPA will notify the manufacturer and may request further information or revisions. If the change is deemed not in compliance with regulatory standards, the manufacturer may have to revert the modification or submit an entirely new registration application.

5. Post-Approval Monitoring

After a change is approved, the manufacturer is required to ensure that:

  • The updated device continues to meet post-market surveillance and adverse event reporting requirements.
  • Changes are communicated appropriately in product labeling, instructions for use, and marketing materials.

6. Timelines and Deadlines

  • Notification for minor changes is usually due within 30-60 days after implementation.
  • Major changes may take several months to review and approve, depending on the complexity.
  • In certain cases, such as critical safety-related changes, the NMPA may expedite the review process.

Conclusion

In China, the NMPA has a comprehensive system for managing changes to registered medical devices. The process ensures that any change, whether minor or major, does not compromise the device's safety, efficacy, or compliance with Chinese regulations. Manufacturers need to carefully evaluate the nature of the changes and follow the appropriate procedures for notification or application to maintain regulatory compliance and avoid disruptions in market access.

Contact Us:

Whatsapp or Wechat:+86 15816864648;email address:hito.lin@grzan.cn

1(6).jpg